On November 1st, 2023, the US FDA approved Phathom Pharmaceuticals’ VOQUEZNA for healing treatment of erosive Gastroesophageal Reflux Disease (GERD). Around 20% of people suffer from GERD, where stomach acid moves up into the esophagus. With erosive GERD, this acid reflux causes damage to throat tissue. This is painful, but can also lead to complications and a worsening condition. Though current medications exist, over half of patients with erosive GERD continue to have symptoms. Potassium-competitive acid blockers (PCABs) are a new class of acid-fighting medications that block acid production in the stomach. These have been called the “next generation” of proton-pump inhibitors. VOQUEZNA is a PCAB medication and has shown superior activity in clinical trials. ENCORE Research Group is proud to have participated at two sites, ENCORE Borland Groover Clinical Research in Jacksonville, FL and Nature Coast Clinical Research in Inverness, FL. Phathom Pharmaceuticals expects the VOQUEZNA to be commercially available in December, 2023.